Article

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma

Author(s):

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

multiple myeloma

Ciltacabtagene autoleucel (cilta-cel; Carvykti) produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma (RRMM) treated at 8 sites in China.1 Investigators said the results from the pivotal phase 2 CARTIFAN-1 trial (NCT03758417) were nearly identical to those observed in US patients in the CARTITUDE-1 trial (NCT03548207).

In CARTIFAN-1, the BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy induced an overall response rate (ORR) of 89.6% (95% CI, 77.3%-96.5%). The median time to first response was 0.95 months (95% CI, 0.9-5.2).

At a median follow-up of 18.0 months (range, 0.2-28.0), 77.1% (95% CI, 62.7%-88.0%) of patients achieved a complete response (CR) or better. The median time to CR or better was 3.32 months (range, 0.9-15.1).

Six patients had progressive disease, 4 due to new extramedullary plasmacytoma development and/or lytic bone lesions.

Data from the 1b/2 CARTITUDE-1 trial presented at the 2022 ASCO Annual Meeting showed that cilta-cel induced an ORR of 97.9% (95% CI, 92.7%-99.7%) among 97 evaluable US patients, including a stringent CR rate of 82.5% (95% CI, 73.4%-89.4%). Moreover, 94.8% of patients experienced a very good partial response or better.2

Previous data from CARTITUDE-1 showed that at a median follow-up of 21.7 months, patients achieved an ORR of 98.0%, with a stringent CR rate of 82.5%.3 The FDA approved cilta-cel in February 2022 for the treatment of adults with RRMM following 4 or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.4

CARTIFAN-1 is an ongoing, open-label, confirmatory study evaluating the efficacy and safety of cilta-cel in Chinese patients with RRMM (N = 48). Investigators sought to assess the agent in Chinese patients, a population that is racially and ethnically distinct from the US-based CARTITUDE-1 study population. Notably, cilta-cel was evaluated in the context of Chinese medical practice and standard of care.

Eligible patients were diagnosed with myeloma per International Myeloma Working Group criteria and received 3 or more prior lines of therapy, including a PI and an IMiD. Unlike CARTITUDE-1, patients were not required to have received an anti-CD38 antibody because China had not approved such an agent when enrollment began. Patients were excluded if they had previous CAR T-cell therapy or BCMA-targeted therapy, or were positive for hepatitis B virus (HBV).

Patients received a single infusion of cilta-cel at a target dose 0.75 × 106 CAR T cells/kg. The median dose was 0.67 × 106 (range, 0.42-0.84 × 106) CAR T cells/kg.

Patients who initially benefited from the treatment could receive another dose in the event of disease progression at investigator discretion. Investigators measured MRD negativity (10−5 threshold) using flow cytometry on bone marrow aspirate.

The median number of previous lines of therapy was 4 (range, 3-9) and 31.3% of patients were triple-class exposed. In the study population, 85.4% of patients were PI-refractory, 91.7% were IMiD-refractory, 79.2% were both PI- and IMiD-refractory, 27.1% were daratumumab (Darzalex)-refractory, 18.8% were triple-class refractory, and 97.9% were refractory to their last line of therapy. Seventeen (35.4%) patients had previously undergone autologous stem cell transplantation (ASCT).

ORR was the primary end point. Secondary end points included progression-free survival (PFS), overall survival (OS), and incidence and severity of adverse events (AEs).

The median patient age was 61.0 years (range, 30-72) at baseline. The median time from diagnosis to cilta-cel infusion was 3.7 years (range, 1.4-10.2). All patients had evaluable bone marrow biopsy or aspirate samples; 20.8% had 30% to 60% of plasma cells, and 16.7% had 60% or more plasma cells. Twenty-one patients (43.8%) had a high-risk cytogenetic profile, 22.9% had t(4,14), 20.8% had del17p, and 0% had t(14;16), and 5 patients (10.4%) had extramedullary plasmacytomas.

Thirty-eight patients remained on study at the July 19, 2021, data cutoff.

Of 40 patients with evaluable samples, 39 (97.5%; 95% CI, 86.8%-99.9%) achieved MRD negativity. Thirty-five of these patients also had CR or better.

Median duration of response (DOR) was not reached. Of 43 responders, 67.2% had a DOR of 18 months or more. Thirty-three patients were still in response at the data cutoff, including 1 patient who received a cilta-cel dose below the target range and maintained stringent CR for 28 months.

The median PFS was not reached. The PFS rate was 77.0% (95% CI, 62.3%-86.5%) at 12 months and 66.8% (95% CI, 49.4%-79.4%) at 18 months. The median overall survival (OS) was not reached, and the 18-month OS rate was 78.7% (95% CI, 64.0%-88.0%).

Forty-seven patients experienced cytokine release syndrome (CRS), including 17 with grade 3/4 CRS. The median onset time was 7 days (range, 2-10) with a median duration of 5 days (range, 2-32). Forty-six (95.8%) patients received supportive measures to treat CRS, and 90.4% of cases resolved by data cutoff.

Five cases of CRS had not resolved by death. Five patients experienced second wave CRS and 3 patients experienced hemophagocytic lymphohistiocytosis.

Ten patients died following cilta-cel infusion, 2 within the first 30 days (before first disease evaluation) and the remainder within 60 days (n = 4) or within 100 days (n = 4). Investigators determined that 8 of the deaths were treatment related.

Forty-one (85.4%) patients experienced infections, 28 (37.5%) of whom experienced grade 3/4 infections. The most common infections were pneumonia (35.4%), upper respiratory tract infection (33.3%), and herpes zoster (18.8%). Five (10.4%) patients had HBV reactivation, and 3 (6.3%) additional patients had new HBV infections.

All patients experienced treatment-emergent AEs (TEAEs) and 40 (83.3%) experienced grade 3/4 TEAEs. The most common grade 3/4 hematologic TEAEs were neutropenia (97.9%), leukopenia (93.8%), lymphopenia (91.7%), thrombocytopenia (54.2%), and anemia (52.1%).

The most common nonhematologic grade 3/4 TEAEs were pneumonia (31.3%), hypokalemia (22.9%), increased aspartate aminotransferase (20.8%), increased gamma-glutamyl transferase (16.7%), and increased alanine aminotransferase (10.4%).

Investigators recorded a single fatal TEAE, a case of pneumonia.

References

  1. Mi JQ, Zhao W, Jing H, Fu W, et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor-t-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. Published online October 21, 2022. doi:10.1200/JCO.22.00690
  2. Usmani SZ, Martin TG, Berdeja JG, et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): two years post LPI. J Clin Oncol. 2022;40(suppl 16):8028. doi:10.1200/JCO.2022.40.16_suppl.8028
  3. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell Maturation Antigen-directed Chimeric Antigen Receptor T-cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(suppl 1):549. doi:10.1182/blood-2021-146060
  4. US FDA approves Carvykti (ciltacabtagene autoleucel), Janssen’s first cell therapy, a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma. News release. Janssen. February 28, 2022. Accessed October 27, 2022. https://bit.ly/35yWwjv
Related Videos
Ajai Chari, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Minoo Battiwalla, MD, MS, director, Blood Cancer Outcomes Research, Sarah Cannon Research Institute, TriStar Medical Group
Rahul Banerjee, MD, FACP
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD